Literature DB >> 1701792

Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing.

E Vivier1, P Morin, C O'Brien, B Druker, S F Schlossman, P Anderson.   

Abstract

NK cells are large granular lymphocytes capable of killing certain tumor cells and virally infected cells in a non-MHC-restricted manner. NK cells can also effect an antibody dependent cytotoxicity that is triggered by CD16, an FcR for IgG. In NK cells, CD16 is expressed in association with zeta, a signal transducing subunit of the TCR complex. Here we show that, just as T cell activation via the TCR complex results in tyrosine phosphorylation of zeta TCR, NK cell activation via CD16 results in tyrosine phosphorylation of zeta NK. Whereas antibody-dependent cytotoxicity also results in tyrosine phosphorylation of zeta, natural cytotoxicity does not. Our results indicate that zeta functions as a transducing element for antibody dependent, but not antibody independent killing by NK cells. Consequently, NK cells are likely to express at least two distinct receptor complexes capable of triggering cytolytic effector function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1701792

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  Functions of the Fc receptors for immunoglobulin G.

Authors:  B K Flesch; J Neppert
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity.

Authors:  O Mandelboim; P Malik; D M Davis; C H Jo; J E Boyson; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

3.  Identification of tissue-infiltrating lymphocytes expressing PEN5, a mucin-like glycoprotein selectively expressed on natural killer cells.

Authors:  E Vivier; M Munroe; P Ariniello; P Anderson
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

4.  CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells.

Authors:  Binqing Fu; Fuyan Wang; Rui Sun; Bin Ling; Zhigang Tian; Haiming Wei
Journal:  Immunology       Date:  2011-04-21       Impact factor: 7.397

5.  Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions.

Authors:  Ilwoong Hwang; Tianxiang Zhang; Jeannine M Scott; Ae Ra Kim; Taehyung Lee; Tejaswi Kakarla; Ahrom Kim; John B Sunwoo; Sungjin Kim
Journal:  Int Immunol       Date:  2012-09-07       Impact factor: 4.823

6.  Inhibition of selective signaling events in natural killer cells recognizing major histocompatibility complex class I.

Authors:  D S Kaufman; R A Schoon; M J Robertson; P J Leibson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

7.  Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.

Authors:  M Kawamura; D W McVicar; J A Johnston; T B Blake; Y Q Chen; B K Lal; A R Lloyd; D J Kelvin; J E Staples; J R Ortaldo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  Tyrosine phosphorylation provides an early and requisite signal for the activation of natural killer cell cytotoxic function.

Authors:  K J Einspahr; R T Abraham; B A Binstadt; Y Uehara; P J Leibson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

Review 9.  Endocytosis and intracellular trafficking of human natural killer cell receptors.

Authors:  Madhan Masilamani; Giovanna Peruzzi; Francisco Borrego; John E Coligan
Journal:  Traffic       Date:  2009-08-05       Impact factor: 6.215

10.  Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.

Authors:  Q Zhou; A Gil-Krzewska; G Peruzzi; F Borrego
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.